Ulrik Bjørn Andersen

Ulrik Bjørn Andersen

Auto-generated profile, based on publicly available information

Ulrik Bjørn Andersen

Department of Clinical Physiology and Nuclear Medicine Copenhagen University Hospital, Rigshospitalet Glostrup Denmark

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
MRMark Reinhard
Mark Reinhard
KSKaroline Schousboe
Karoline Schousboe
UAUlrik B. Andersen
Ulrik B. Andersen
NBNiels Henrik Buus
Niels Henrik Buus
JRJesper Moesgaard Rantanen
Jesper Moesgaard Rantanen
KCKent Lodberg Christensen
Kent Lodberg Christensen
Background: The aim of this study was to prospectively evaluate the effects of renal artery stenting in consecutive patients with severe atherosclerotic renal artery stenosis and high‐risk clinical presentations as defined in a national protocol developed in 2015. Methods and Results: Since the protocol was initiated, 102 patients have been referred for revascularization according to the following high‐risk criteria: severe renal artery stenosis (≥70%) with true resistant hypertension, rapidly declining kidney function, or recurrent heart failure/sudden pulmonary edema. At baseline, the mean 24‐hour ambulatory systolic blood pressure was 166.2 mm Hg (95% CI, 162.0–170.4), the defined daily dose of antihypertensive medication was 6.5 (95% CI, 5.8–7.3), and the estimated glomerular filtration rate was 41.1 mL/min per 1.73m 2 (95% CI, 36.6–45.6). In 96 patients with available 3‐month follow‐up data, mean 24‐hour ambulatory systolic blood pressure decreased by 19.6 mm Hg (95% CI, 15.4–23.8; P< 0.001), the defined daily dose of antihypertensive medication was reduced by 52% (95% CI, 41%–62%; P <0.001), and estimated glomerular filtration rate increased by 7.8 mL/min per 1.73m 2 (95% CI, 4.5–11.1; P <0.001). All changes persisted after 24 months follow‐up. Among 17 patients with a history of hospitalization for acute decompensated heart failure, 14 patients had no new episodes after successful revascularization. Conclusions: In this prospective cohort study, we observed a reduction in blood pressure and antihypertensive medication, an increase in estimated glomerular filtration rate, and a decrease in new hospital admissions attributable to heart failure/sudden pulmonary edema after renal artery stenting. Registration: URL: https://clinicaltrials.gov . Identifier: NCT02770066.


11 September 2018 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
BHBryan Thomas Haddock
Bryan Thomas Haddock
SFSusan T. Francis
Susan T. Francis
HLHenrik B.W. Larsson
Henrik B.W. Larsson
UAUlrik B. Andersen
Ulrik B. Andersen
Background: Renal flow abnormalities are believed to play a central role in the pathogenesis of nephropathy and in primary and secondary hypertension, but are difficult to measure in humans. Handgrip exercise is known to reduce renal arterial flow (RAF) by means of increased renal sympathetic nerve activity. Methods: To monitor medullary and cortical oxygenation under handgrip exercise–reduced perfusion, we used contrast- and radiation-free magnetic resonance imaging (MRI) to measure regional changes in renal perfusion and blood oxygenation in ten healthy normotensive individuals during handgrip exercise. We used phase-contrast MRI to measure RAF, arterial spin labeling to measure perfusion, and both changes in transverse relaxation time (T2*) and dynamic blood oxygenation level–dependent imaging to measure blood oxygenation. Results: Handgrip exercise induced a significant decrease in RAF. In the renal medulla, this was accompanied by an increase of oxygenation (reflected by an increase in T2*) despite a significant drop in medullary perfusion; the renal cortex showed a significant decrease in both perfusion and oxygenation. We also found a significant correlation (R 2=0.8) between resting systolic BP and the decrease in RAF during handgrip exercise. Conclusions: Renal MRI measurements in response to handgrip exercise were consistent with a sympathetically mediated decrease in RAF. In the renal medulla, oxygenation increased despite a reduction in perfusion, which we interpreted as the result of decreased GFR and a subsequently reduced reabsorptive workload. Our results further indicate that the renal flow response’s sensitivity to sympathetic activation is correlated with resting BP, even within a normotensive range.

26 September 2016 in Scandinavian Journal of Clinical and Laboratory Investigation
Verified
Journal Article
Closed access
VCVanja Cejvanovic
Vanja Cejvanovic
CACamilla Asferg
Camilla Asferg
LKLaura Kofoed Kjær
Laura Kofoed Kjær
UAUlrik B. Andersen
Ulrik B. Andersen
Allan LinnebergAllan Linneberg
Allan Linneberg
HPHenrik Enghusen Poulsen
Henrik Enghusen Poulsen
Objectives: The aim of our study was to investigate if the 24-hour excretion of the urinary markers for oxidative stress to DNA and RNA, measured as 8-oxo-7,8-dihydro-2’-deoxyguanosine (8-oxodG) and 8-oxo-7,8-dihydro-guanosine (8-oxoGuo), respectively, were increased in obese individuals with or without hypertension compared to lean controls. Methods: A total of 63 obese hypertensive men (obeseHT), 40 obese normotensive men (obeseNT) and 27 lean normotensive men (leanNT) were included in the study. Body mass index (BMI) was between 20.0 and 24.9 kg/m2 in leanNT participants and ≥30 kg/m2 in obese participants. Hypertension was defined as a mean 24-hour systolic ambulatory blood pressure (AMBP) ≥ 130 mmHg or a mean 24-hour diastolic AMBP ≥80 mmHg and normotension as mean 24-hour AMBP <130/80 mmHg. Twenty-four hour urinary 8-oxoGuo and 8-oxodG excretion (nmol/24 h) were measured by a validated liquid chromatography-tandem mass spectrometry method (UPLC-MS/MS). Results: Urinary 8-oxoGuo excretion was (median and [interquartile range]) 30.8 [27.8–32.2] nmol/24 h in leanNT, 36.8 [31.3–40.2] nmol/24 h in obeseNT and 40.6 [31.7–48.5] nmol/24 h in obeseHT. The difference was statistically significant (p = .002) and post hoc tests showed a significant difference between leanNT and obeseHT (p = .001) as well as obeseNT (p = .002), whereas the two obese groups did not differ (p = .6). No statistically significant differences in 8-oxodG concentrations were observed between the three groups (p = .3). Conclusion: The measurement of urinary excretion of 8-oxoGuo suggests that obesity in men, but not hypertension, is associated with increased oxidative damage to RNA.

8 January 2014 in BMJ Open
Verified
Journal Article
Open access
PDF file
PIPelle L Ishøy
Pelle L Ishøy
FKFilip Knop
Filip Knop
BBBrian V Broberg
Brian V Broberg
LBLone Baandrup
Lone Baandrup
BFBirgitte Fagerlund
Birgitte Fagerlund
BEBjørn H Ebdrup
Bjørn H Ebdrup
Introduction Antipsychotic medication is widely associated with dysmetabolism including obesity and type 2 diabetes, cardiovascular-related diseases and early death. Obesity is considered the single most important risk factor for cardiovascular morbidity and mortality. Interventions against antipsychotic-associated obesity are limited and insufficient. Glucagon-like peptide-1 (GLP-1) receptor agonists are approved for the treatment of type 2 diabetes, but their bodyweight-lowering effects have also been recognised in patients with non-diabetes. The primary endpoint of this trial is weight loss after 3 months of treatment with a GLP-1 receptor agonist (exenatide once weekly) in patients with non-diabetic schizophrenia with antipsychotic-associated obesity. Secondary endpoints include physiological and metabolic measurements, various psychopathological and cognitive measures, and structural and functional brain MRI. Methods and analysis 40 obese patients with schizophrenia or schizoaffective disorder treated with antipsychotic drugs will be randomised to subcutaneous injection of exenatide once weekly (2 mg) or placebo for 3 months, adjunctive to their antipsychotic treatment. Ethics and dissemination The trial has been approved by the Danish Health and Medicines Authority, the National Committee on Health Research Ethics and the Danish Data Protection Agency. Trial participation presupposes theoral and written patient informed consent. An external, independent monitoring committee (Good Clinical Practice Unit at Copenhagen University Hospital) will monitor the study according to the GCP Guidelines. Trial data, including positive, negative and inconclusive results, will be presented at national and international scientific meetings and conferences. Papers will be submitted to peer-reviewed journals. Trial registration ClinicalTrials.gov identifier: NCT01794429; National Committee on Health Research Ethics project number: 36378; EudraCT nr: 2012-005404-17; The Danish Data Protection Agency project number: RHP-2012-027.

12 February 2014 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
ARAnne Q Rasmussen
Anne Q Rasmussen
UAUlrik B Andersen
Ulrik B Andersen
NJNiklas Rye Jørgensen
Niklas Rye Jørgensen
Peter SchwarzPeter Schwarz
Peter Schwarz
Introduction: We present the case of a patient with non-infectious osteomyelitis of the mandible, which is a recognized but unusual condition of unknown cause. Case presentation: A 14-year-old Caucasian girl presented with pain and edema in the left side of her jaw. A clinical examination led to a diagnosis of osteomyelitis and she was treated with antibiotics. Our patient continued antibiotic treatment for osteomyelitis and underwent decortication. Histology based on a biopsy showed new bone formation and chronic inflammation, and a diagnosis of sclerotic osteomyelitis was made. Over the next few years, she experienced pain on the left side of her jaw and increasing edema, and the size of the left side of her jaw bone increased. She was then sent to our Department of Medicine at the age of 16 years. Her symptoms included pain in the left side of her jaw that scored 4 on a visual analogue scale of 1 to 10. A diagnosis of bone disease was made based on bone scintigraphy and single photon emission computed tomography that showed hot spots in the affected left side of the jaw. Our patient was treated with a single dose of intravenous zoledronic acid (5mg) at age 17 years, which was repeated after 12 months. The bone pain was significantly reduced six months after treatment and had disappeared 24 months after treatment. Conclusion: We report an unusual localization of non-infectious osteomyelitis of the jaw in a young woman. Even though the presentation was in the jaw, her condition improved after intravenous bisphosphonate treatment, as evaluated by reduced clinical symptoms, bone turnover evaluation as assessed by biochemical bone markers, and reduced activity on bone scintigraphy.